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Abstract: The ability of amylin to inhibit gastric emptying and glucagon secretion in rats is reduced under
hypoglycemic conditions. These effects are considered part of a fail-safe mechanism that prevents amylin
from further decreasing nutrient supply when blood glucose levels are low. Because these actions and
amylin-induced satiation are mediated by the area postrema (AP), it is plausible that these phenomena
are based on the co-sensitivity of AP neurons to amylin and glucose. Using hyperinsulinemic glucose
clamps in unrestrained and freely-feeding rats, we investigated whether amylin’s ability to inhibit food
intake is also reduced by hypoglycemia (HYPO). Following an 18 h fast, rats were infused with insulin
and glucose for 45 min to clamp blood glucose at baseline levels (between 90 and 100 mg/dL). HYPO
(approximately 55 mg/dL) was induced between 45 and 60 min and then maintained for the remainder of
the clamp. Rats were injected with amylin (20 µg/kg) or saline and offered normal chow at 85 min. Food
intake was measured at 30 and 60 min after amylin. Control hyperinsulinemic/euglycemic (EU) rats were
maintained at approximately 150 mg/dL (which is a physiological periprandial glucose level) before and
after amylin injection. Terminal experiments tested the effect of amylin to induce the phosphorylation of
ERK, a marker of amylin action in the AP, in EU and HYPO conditions. Amylin significantly reduced 30-
and 60-min food intake in EU rats, but the effect at 60-min was attenuated in HYPO rats. Interestingly,
glucose infusion rate had to be dramatically reduced at meal onset in saline-treated, but not in amylin-
treated, EU or HYPO rats; this suggests that meal-related glucose appearance in the blood was inhibited
by amylin under both EU and HYPO. Finally, amylin induced a similar pERK response in the AP in EU
and HYPO rats. We conclude that amylin’s action to decrease eating is blunted in hypoglycemia, and
this effect seems to be downstream from amylin-induced pERK in AP neurons. These data allow us to
extend the idea of a hypoglycemic brake on amylin’s actions to its food intake-reducing effect, but also
demonstrate that amylin can buffer meal-induced glucose appearance at EU and HYPO levels.
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A B S T R A C T   
The ability of amylin to inhibit gastric emptying and glucagon secretion in rats is reduced under hypoglycemic 
conditions. These effects are considered part of a fail-safe mechanism that prevents amylin from further 
decreasing nutrient supply when blood glucose levels are low. Because these actions and amylin-induced sati-
ation are mediated by the area postrema (AP), it is plausible that these phenomena are based on the co-sensitivity 
of AP neurons to amylin and glucose. Using hyperinsulinemic glucose clamps in unrestrained and freely-feeding 
rats, we investigated whether amylin’s ability to inhibit food intake is also reduced by hypoglycemia (HYPO). 
Following an 18 h fast, rats were infused with insulin and glucose for 45 min to clamp blood glucose at baseline 
levels (between 90 and 100 mg/dL). HYPO (approximately 55 mg/dL) was induced between 45 and 60 min and 
then maintained for the remainder of the clamp. Rats were injected with amylin (20 µg/kg) or saline and offered 
normal chow at 85 min. Food intake was measured at 30 and 60 min after amylin. Control hyperinsulinemic/ 
euglycemic (EU) rats were maintained at approximately 150 mg/dL (which is a physiological periprandial 
glucose level) before and after amylin injection. Terminal experiments tested the effect of amylin to induce the 
phosphorylation of ERK, a marker of amylin action in the AP, in EU and HYPO conditions. Amylin significantly 
reduced 30- and 60-min food intake in EU rats, but the effect at 60-min was attenuated in HYPO rats. Inter-
estingly, glucose infusion rate had to be dramatically reduced at meal onset in saline-treated, but not in amylin- 
treated, EU or HYPO rats; this suggests that meal-related glucose appearance in the blood was inhibited by 
amylin under both EU and HYPO. Finally, amylin induced a similar pERK response in the AP in EU and HYPO 
rats. We conclude that amylin’s action to decrease eating is blunted in hypoglycemia, and this effect seems to be 
downstream from amylin-induced pERK in AP neurons. These data allow us to extend the idea of a hypoglycemic 
brake on amylin’s actions to its food intake-reducing effect, but also demonstrate that amylin can buffer meal- 
induced glucose appearance at EU and HYPO levels.   
1. Introduction 
The mammalian body has several remarkable and intricate mecha-
nisms to keep the organism at equilibrium. The interplay among hor-
mones released from the pancreas represent one such mechanism for 
maintaining blood glucose. Insulin released from the pancreatic beta 
cells regulates glucose uptake from the blood, and glucagon from the 
alpha cells promotes utilization of endogenous glucose stores and 
gluconeogenesis when blood glucose is low. Amylin is a second beta-cell 
hormone with actions relevant for the control of nutrient metabolism, 
interacting with both insulin and glucagon. In response to nutrient 
stimuli, amylin is co-secreted with insulin and complements insulin 
action by limiting the rate of glucose appearance into the blood. Amylin 
achieves this through three major actions: the inhibition of postprandial 
glucagon secretion, slowing gastric emptying and by inducing satiation. 
This collectively demonstrates that amylin has important glycemic 
buffering properties that prevent excessive flooding of glucose into the 
blood, particularly during the prandial and postprandial phases (for 
review, see [1,2]). 
Because of these properties, soon after its discovery, amylin was 
considered an interesting candidate to supplement insulin therapy in 
people suffering from type 1 and late-stage type 2 diabetes, and the 
amylin analogue pramlintide was eventually approved for use by the 
FDA. However, an early concern was whether amylin would be 
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detrimental if a person requiring insulin had a hypoglycemic epi-
sode—increased glucagon secretion, accelerated gastric emptying and 
nutrient ingestion are critical measures for restoring glucose to healthy 
levels, measures which could inadvertently be blocked by amylin. 
Interestingly, it was found that under hypoglycemic conditions (35—65 
mg/dL), amylin neither blocked glucagon release nor slowed gastric 
emptying. The presence of a protective hypoglycemic brake was sug-
gested, which seems to prevent amylin-induced inhibitions of gastric 
emptying and glucagon secretion when blood glucose levels are criti-
cally low [3-5]. However, whether this protective mechanism blocks all 
glucose buffering of amylin, including its effect on satiation remained to 
be investigated. Furthermore, the mechanism underlying this brake has 
not been determined. The area postrema (AP) is the primary brain site 
mediating amylin’s effects. Peripheral administration of amylin leads to 
increases in various markers of neuronal activation in the AP, including 
the phosphorylation of ERK (pERK) [6], and lesions of the AP reduce 
amylin’s ability to reduce food intake [7], suppress glucagon and slow 
gastric emptying [8]. In addition to responding to amylin, the vast 
majority of these AP neurons are also glucose responsive; their rate of 
spontaneous activity decreases with decreasing glucose concentrations 
[9]. This has led to the suggestion that a certain level of glucose may be 
necessary or permissive of amylin action in the AP. Along this line of 
reasoning, low glucose levels may de-sensitize AP neurons to stimulation 
by amylin. 
The primary goal of this study was to test the hypothesis that hy-
poglycemia limits the acute inhibitory effect of amylin on eating, in line 
with what was observed for glucagon release and gastric emptying. 
Secondly, we wanted to determine if glucose levels directly influence the 
ability of amylin to activate downstream signaling pathways, such as the 
phosphorylation of ERK, which seems to be functionally relevant for 
amylin action [6], in AP neurons. To test these hypotheses, we devel-
oped a novel hyperinsulinemic glucose clamp that allowed 
freely-moving rats to spontaneously eat while glycemic levels were 
maintained at either a euglycemic (EU) or hypoglycemia (HYPO) target. 




Male Wistar rats (200—225 g body weight on arrival) were pur-
chased from Janvier, France. Rats were individually-housed in hanging, 
stainless steel wire-mesh cages. All cages were furnished with a plastic 
tunnel and nest-building material. Rats were maintained in a 
temperature-controlled environment (21± 2 ◦C), on a 12 h/12 h light- 
dark cycle. Water and standard chow (D3430; Provimi Kliba AG, Kai-
seraugst, Switzerland) were accessible ad libitum, unless otherwise 
indicated. All experiments were performed with the approval of the 
veterinary office of the Canton Zurich, Switzerland, and in accordance 
with the European Union Directive 2010/63/EU on the protection of 
animals used for scientific purposes. 
2.2. Surgical preparation for hyperinsulinemic/eu- and hypoglycemic 
clamps 
Chronic catheters were implanted in the carotid artery for frequent 
and stress-free blood sampling, and in the jugular vein for peripheral 
infusion of insulin and glucose during glycemic clamps. Approximately 
one week prior to experiments, rats were food-deprived overnight and 
received subcutaneous injections of antibiotics (enrofloxacin, 10 mg/kg) 
and analgesics (meloxicam, 2.5 mg/kg) prior to surgery. Rats were 
anesthetized using ketamine (80 mg/kg, i.p.; Narketan10) and xylazine 
(6 mg/kg, i.p.; Rompun 2%). Incision sites were shaved and disinfected 
with Betadine, and Vitamin-A ointment was applied to the eyes for 
protection. During surgery, rats received oxygen via nose cone (1.4 L/ 
min), and body temperature was monitored and maintained with a 
rectal probe that automatically adjusted the temperature of a heating 
pad below the rat. Catheters (Silastic ID 0.51 x OD 0.94 mm; Instech 
Solomon, Plymouth Meeting, USA) were implanted in the carotid artery 
and in the jugular vein, and fixed to a mesh connector at the site between 
the scapulae where they were exteriorized. Blood flow was confirmed in 
both lines, and catheters were sealed with an autoclaved lock solution 
(100 IU/mL insulin in 50% glycerol) until the day of experiment. Rats 
were placed in a warmed chamber to recover from anesthesia, and 
received a post-operative dose of Flunixin (1 mg/kg, s.c.) and 5 ml of 
warm saline supplemented with 5% glucose (s.c.). Rats continued to 
receive subcutaneous injections of antibiotics and analgesics (dosing as 
above), and 0.9% saline supplemented with 5% glucose daily for the first 
1 to 3 days after surgery. 
2.3. Establishing a glucose clamp paradigm in freely-feeding rats 
As glycemic clamps are typically performed in anesthetized or fasted 
rodents, we executed several pilot studies to establish three critical 
components of our new clamp paradigm that was performed in freely- 
feeding rats. 
2.3.1. Determine glucose curves during a meal to establish euglycemic 
clamp target 
The first pilot was performed to determine basal (after 18 h of fast-
ing) and postprandial glucose levels in rats. Rats (n = 3) were prepared 
for the clamp procedure, however only saline was infused through the 
jugular vein catheter. At time point 0, fasted blood glucose was 
measured in arterial blood (82.8 ± 7.2 mg/dL), after which rats were 
given access to standard chow and immediately began to eat. Glucose 
was measured every 5 min for the first 5 time points, and every 10 min 
thereafter; food intake was measured at 30 and 60 min. As shown in 
Fig. 1, glucose levels already began to rise after 5 min, and peaked at 30 
min from meal onset, reaching 156.8 ± 9.0 mg/dL. From there, glucose 
levels gradually decreased to 133.3 ± 1.8 mg/dL at 60 min after meal 
onset. Rats consumed 5.7 ± 0.3 g of food at 30 min, and 6.8 ± 0.6 g at 60 
min, which is similar to intake in unmanipulated rats [7, 10]. Based on 
these findings, our target for physiological EU during the hyper-
insulinemic/EU clamps was 150 mg/dL. 
2.3.2. Determine infusion rates of insulin 
We next established the insulin infusion rate necessary to maintain 
hypoglycemia in freely-feeding rats. We found that a typical insulin 
infusion rate of 25 mU/kg/min [11] was insufficient to maintain hy-
poglycemia when test rats (n = 2) began eating. To maintain a glucose 
level of approximately 55 mg/dL, it was necessary to increase the insulin 
infusion rate by approximately 4-fold. We therefore retested rats using 
125 mU/kg/min insulin, which was sufficient to maintain a state of 
hypoglycemia in freely feeding rats. Based on these findings, all studies 
were performed using an insulin infusion rate of 125 mU/kg/min, which 
enabled constant insulin infusion conditions for the duration of each 
clamp. In order to account for this high insulin infusion rate during the 
fasted portions of the clamps, a 50% glucose solution was infused for the 
duration of each clamp. 
2.3.3. Determine glucose infusion rate (GIR) adjustment after amylin 
Finally, we observed during our pilot tests the importance of 
adjusting GIR, particularly after amylin treatment. We noted that in rats 
receiving saline injection, in order to maintain the target glycemic level, 
it was necessary to reduce their GIR to account for the meal-derived 
glucose. In rats maintained in a hypoglycemic state, it was often 
necessary to reduce the GIR to 0 mg/kg/min. However, if this same 
reduction was performed in rats receiving amylin prior to the meal, their 
glucose levels fell below our hypoglycemic target, and in some cases 
below 35 mg/dL, which ultimately affected their fine-motor coordina-
tion and ability to eat. Consequently, we found it necessary to increase 
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the GIR in rats receiving amylin treatment, to prevent a drop in glucose 
level and thus preserving the rats’ ability to eat during the clamp. We 
also observed that 55 mg/dL was a HYPO level at which rats maintained 
the fine-motor skills to eat normally. 
2.4. Amylin action during hyperinsulinemic euglycemic and hypoglycemic 
clamps 
A schematic timeline of the clamp experiments is shown in Fig. 2. 
Rats were fasted 18 h before the start of the experiment and placed in 
Macrolon cages with bedding for infusion. One hour before the start of 
the clamp, rats were connected to a tethered dual-channel swivel system 
(Instech Solomon, Plymouth Meeting, USA), and saline was infused into 
the jugular vein at a rate of 11 μl/min. Baseline glucose was measured 30 
and 0 min before the start of the clamp. At time point 0 min, insulin (125 
mU/kg/min; Actrapid HM, NovoNordisk) and glucose (50% glucose; 
variable) infusions were started and maintained for 150 min. Arterial 
blood samples were collected every 5 min for glucose determination 
(Breeze2, Bayer AG), with larger samples collected at −30, 85, 100, and 
145 min for insulin measurement. At time point 45 min, glucose infusion 
was either increased to reach the pre-determined physiological post-
prandial euglycemic level of 150 mg/dL (EU), or decreased to maintain a 
hypoglycemic level of approximately 55 mg/dL (HYPO). To test the 
anorectic effect of amylin under the glycemic clamp paradigm, 
following maintenance of the target glycemic level for 20 to 25 min, 
saline or amylin (20 μg/kg; s.c.; 1 mL/kg injection volume) was injected 
(85 min from the start of the clamp), and pre-weighed chow pellets (9 g) 
were given to the animals. Remaining food pellets and crumbs were 
collected from the cage and manually weighed at 30 and 60 min after 
amylin administration. Insulin was measured in serum in duplicate 
using Milliplex Map Rat Endocrine kit (RENDO-85 K, Millipore). EU and 
HYPO clamps were run as two independent experiments in different 
cohorts of rats. 
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Fig. 1. Determination of postprandial glycemic levels. 
Mean ± SD arterial glucose levels and food intake 
measured in previously fasted rats (n = 3) for 60 min. 
Rats were attached to a weighted swivel tether and 
saline was infused via the jugular vein catheter for 60 
min prior to food access. At timepoint 0 min, chow was 
given to the rats and blood glucose was measured via 
the carotid artery catheter every 5 to 10 min. A peak 
glucose level of 156.8 ± 9.0 mg/dL was reached 30 min 
after meal initiation, and by 60 min glucose levels 
decreased to 133.3 ± 1.8 mg/dL. This range therefore 
represented our target for the hyperinsulinemia-EU 
clamps.   
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Fig. 2. Experimental timeline for the hyperinsulinemic-euglycemic (EU) and -hypoglycemic (HYPO) clamp experiments. Following an 18-hour fast, male Wistar rats 
were attached to a weighted swivel tether and saline was infused via the jugular vein catheter for 60 min. At timepoints −30 and 0 min, baseline blood glucose was 
measured via the carotid artery catheter; blood glucose was then measured every 5 min for the remainder of the clamp. Larger blood samples were collected at −30, 
85, 100, and 145 min for insulin level determination. Beginning at timepoint 0 min, insulin (125 mU/kg/min) and glucose (variable infusion rate) were infused into 
the jugular vein catheter. After 45 min of baseline clamp, over a 15-min period, glucose infusion rates (GIR) were increased to reach target of approximately 150 mg/ 
dL for EU, or reduced to reach the HYPO target of 55 mg/dL. This target level was then maintained for 20–25 min, and at 85 min rats were treated with saline or 
amylin (20 μg/kg; s.c.) and provided with chow. GIRs were adjusted to maintain the target glycemic levels in freely-feeding rats until 145 min, with 30-min food 
intake measured at timepoint 115 min, and 60-min food intake measured 145 min. In the pERK experiment, the same procedure was followed, however, following 
saline or amylin injection at 85 min, food was withheld and rats were deeply anesthetized and perfused 15 min after treatment. 
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2.5. Influence of glycemic state on amylin-induced phosphorylation of 
ERK 
In a final experiment, the influence of the glycemic state on amylin- 
induced neuronal signaling in the AP was investigated in a third cohort 
of rats. Thus, during HYPO or EU clamps, rats received either saline or 
amylin (20 μg/kg; s.c.), and brain tissue was processed for the detection 
of pERK using immunohistochemistry. Rats were randomly assigned 
into one of the following four groups (4–5 rats/group): EU/saline, EU/ 
amylin, HYPO/saline, or HYPO/amylin. The experimental timelines 
were similar to the previous EU and HYPO clamp experiments (See 
Fig. 2). Rats received either saline or amylin at 85 min, but unlike in the 
previous experiments, food was withheld. Fifteen minutes following the 
injection, the final blood samples were collected for glucose and insulin 
measurements, and a bolus of pentobarbital (60 mg/kg, i.v.) was 
administered. Rats were then transcardially perfused with 0.1 M phos-
phate buffer (PB) followed by 4% PFA in PB. Brains were removed, post- 
fixed for two hours in 4% PFA in PB, and then transferred to 20% sucrose 
solution for 36–48 h at 4 ◦C. Brains were frozen in chilled hexane, and 
20-μm coronal brain sections containing the AP were collected using a 
cryostat (Leica CM3050S) and thaw-mounted onto adhesion glass slides. 
Brain sections were immunostained using pERK1/2 antibody (1:1000; 
Cell Signaling Technology #9101), which was visualized using 3,3-dia-
minobenzidine-tetrahydrochloride (DAB) chromogen and quantified as 
described previously [6]. 
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Fig. 3. Effect of amylin on food intake and glucose infusion rate under hyperinsulinemic-euglycemic (EU) and -hypoglycemic (HYPO) clamp conditions. Blood 
glucose levels (A) from saline- (white circles; n = 6) and amylin- (black circles; n = 7) treated rats during EU clamps. Basal fasting glucose levels were maintained 
from 0 to 45 min, at which point, glucose infusion rate (GIR; B) was increased to mimic a postprandial glycemic state between 145 and 155 mg/dL, which was 
maintained from 60 to 145 min of the clamp. Blood glucose levels (C) from saline- (white circles; n = 13) and amylin- (black circles; n = 10) treated rats during HYPO 
clamps. Basal fasting glucose levels were maintained from 0 to 45 min, at which point, GIR (D) was decreased to reach a hypoglycemic state of approximately 55 mg/ 
dL, which was maintained from 60 to 145 min of the clamp. In both EU and HYPO clamps, at 85 min, rats were treated with saline or amylin (20 μg/kg, s.c.) and food 
was provided. Food intake was measured 30 and 60 min later (E). To directly compare the effectiveness of amylin to reduce food intake under EU and HYPO 
conditions, food intake data were represented as the percent of saline control food intake (F) and then analyzed using two-way ANOVA for glycemic state (EU or 
HYPO) and treatment (saline or amylin). The absolute difference in food intake between EU and HYPO amylin-treated rats and their respective saline controls is 
shown in (G). All data are expressed as mean ± SD; symbols denote significant differences between saline- and amylin-treated groups; *p<0.05, 
**p<0.01, ***p<0.001. 
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2.6. Statistical analysis 
All data are shown as mean ± SD. Significance of differences between 
two groups was tested using unpaired t-tests, and data sets with two 
factors (treatment and glycemic level) were analyzed using two-way 
ANOVA, followed by Bonferroni’s multiple comparison when appro-
priate (GraphPad Prism 9 for Mac). A P-value < 0.05 was considered 
statistically significant. 
3. Results 
3.1. Amylin-induced reduction in food intake is preserved during 
hyperinsulinemic/euglycemic clamp 
To determine whether the glycemic state influences the ability of 
exogenous amylin to reduce food intake or buffer meal-induced glucose 
excursions in the blood, rats were first clamped at a euglycemic blood 
glucose level corresponding to the postprandial state (approximately 
150 mg/dL; Fig. 3A). After achieving a steady-state, peripheral amylin 
(20 μg/kg) or vehicle was administered and rats were provided access of 
food. Similar to what was observed in our pilot experiments, immedi-
ately following meal initiation, vehicle-treated rats required a signifi-
cantly greater reduction in GIR to maintain the clamp at 150 mg/dL 
glucose, compared to the reduction required by the amylin-treated 
group (Fig. 3B); we observed a main effect of treatment (F [1,319] =
143.1, P<0.001), and detected individual differences between saline- 
and amylin-treated rats beginning at 85 min (P<0.05). This difference 
was more pronounced between 90 and 140 min (P<0.001), where 
amylin-treated rats required 1.5 to 2 times more exogenous glucose than 
saline-treated rats to maintain the EU clamp. Amylin treatment signifi-
cantly reduced food intake measured at 30 (P<0.001) and 60 min 
(P<0.01) compared to vehicle (Fig. 3E; white and lined bars). By first 
demonstrating that amylin’s effect on food intake is intact during the 
euglycemic clamp, we can conclude that the hyperinsulinemic clamp 
protocol itself does not influence amylin’s ability to reduce food intake. 
3.2. Amylin-induced reduction in food intake is blunted during 
hyperinsulinemic/hypoglycemic clamp 
Next, we investigated if hypoglycemia would interfere with amylin- 
induced reduction in food intake. Rats were clamped at a hypoglycemic 
level that still permitted the fine-motor coordination required to eat (55 
mg/dL, Fig. 3C). When steady-state was achieved, peripheral amylin or 
vehicle was administered and all rats began eating when given access to 
food. In order to maintain HYPO in rats eating a meal, the GIR in vehicle- 
treated rats was lowered prior to the first post-ingestion/injection blood 
sample at minute 85, and was turned to 0 mg/kg/min by minute 95 
(Fig. 3D). In contrast, the amylin-treated rats required an increase in GIR 
from the pre-prandial/pre-injection state, resulting in a main effect of 
amylin treatment (F [1,591] = 945.9, P<0.001), with significant in-
creases in GIR between minutes 85 and 140 compared to the vehicle 
group (P<0.001). Amylin treatment in HYPO rats significantly reduced 
food intake at 30 min after treatment (P<0.01), but not 60, compared to 
vehicle (Fig. 3E; hatched and black bars). 
3.3. Comparison of food intake and circulating insulin levels during 
euglycemic and hypoglycemic clamps 
As a primary objective of these experiments was to determine if 
hypoglycemia alters the ability of acute amylin administration to reduce 
eating, food intake data obtained from the EU and HYPO clamps were 
further analyzed in relation to one another. First, using two-way 
ANOVA, the main effects of amylin treatment and glycemic state were 
analyzed (Fig. 3E). A main effect of treatment (F [1,32] = 25.86, 
P<0.001), but not glycemic state, was detected in the 30 min data, with 
a significant difference between saline and amylin observed in both EU 
(P<0.001) and HYPO (P<0.01) states. At 60 min, a main effect of 
treatment (F [1,32] = 17.68, P<0.001), but not glycemic state, was 
again observed, however a significant reduction of amylin was only 
observed in the EU (P<0.01) and not the HYPO state. To account for 
slight differences in baseline food intake between the EU and HYPO 
clamps, food intake data were also represented as a percentage of each 
group’s saline control (Fig. 3F). As observed in the raw data, a main 
effect of treatment was observed at 30 and 60 min (F [1, 32] = 23.66 and 
15.88, P<0.001 for both). At 30 min, amylin reduced food intake in both 
EU and HYPO states (P<0.01), though the effect of amylin was less 
significant in HYPO rats 60 min after administration (P<0.01 for EU, 
P<0.05 for HYPO). Further, when we calculated the absolute reduction 
in food intake versus the saline control (Fig. 3G), amylin treatment 
reduced 60-min food intake by an average of 3.17 ± 1.86 g (55.5% of 
saline controls) in the EU state, which was significantly more than the 
reduction of 1.58 ± 1.48 g (74.4% of saline controls) in the HYPO state (t 
[15] = 1.99, P<0.05). Thus, even though amylin was able to reduce food 
intake under this specific HYPO condition, the effect was attenuated 
compared to EU. 
Insulin was measured at timepoints −30, 85, 100, and 145 min 
during each clamp, as this could also influence GIR and food intake. 
However, regardless of treatment or target glycemic state, insulin levels 
were not different across groups at any timepoint during the clamp 
procedure (Table 1), confirming the validity of the clamp conditions 
with fixed insulin infusion rates. 
3.4. Glycemic state does not influence amylin-induced pERK in the area 
postrema 
Previous work from our group demonstrated that amylin induces the 
phosphorylation of the signaling molecule ERK in the AP, and that 
blockade of this signaling pathway reduces amylin’s effect on food 
intake [6]. Here we asked whether hypoglycemia influences the 
amylin-induced phosphorylation of ERK in the AP. Fig. 4A shows the 
quantification of the number of neurons positive for pERK in the AP 
collected from rats 15 min after saline or amylin (20 μg/kg) treatment, 
and maintained in the EU or HYPO state. Two-way ANOVA detected a 
main effect of amylin treatment on the number of pERK-positive cells (F 
[1,15] = 17.79, P<0.001); however, no effect of the glycemic state was 
observed. Multiple comparisons demonstrated that amylin induced a 
significant pERK response in the AP of both EU (P<0.05) and HYPO 
(p<0.01) rats. Representative photomicrographs of the AP from HYPO 
rats treated with saline or amylin are shown in Fig. 4B and C. 
4. Discussion 
Advancements in insulin therapy to treat type 1 and type 2 diabetes 
have achieved tremendous benefits in controlling basal and postprandial 
blood glucose levels by using different insulin administration methods 
and combination therapies. In fact, the combination of insulin and 
amylin resulted in a better control of long-term body weight and of 
postprandial glucose excursion compared to insulin monotherapy [12, 
13]. Despite these advances, hypoglycemia remains a serious side effect 
of insulin therapy. Therefore, and because of the success of insulin and 
amylin combination therapy, more research needs to be done to 
Table 1 
Mean ± SD arterial insulin levels (ng/mL) measured during EU and HYPO 
glucose clamps.   
EU/Saline EU/Amylin HYPO/Saline HYPO/Amylin 
Time (min) Mean SD Mean SD Mean SD Mean SD 
¡30 0.48 0.32 0.76 0.85 0.28 0.18 0.56 0.37 
85 3.19 0.31 4.03 0.39 3.29 0.63 3.90 0.99 
100 3.04 0.21 3.95 0.22 3.79 0.66 3.76 0.70 
145 3.41 0.34 4.04 0.36 4.28 1.32 3.99 0.54  
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investigate the function of amylin under such conditions. In this study, 
we investigated the efficacy of amylin under hypoglycemic conditions. 
In particular, we asked whether hypoglycemia limits the acute, food 
intake-reducing effect of amylin to prevent a shortage of nutrient supply. 
To answer this question, we performed hyperinsulinemic-euglycemic 
and -hypoglycemic clamps in male Wistar rats. The results of these 
studies reveal three main findings: 1) Hypoglycemia attenuates the 
acute food intake-reducing effect of amylin. 2) Following amylin treat-
ment, increased GIR is required to maintain glycemic levels compared to 
controls rats, both under EU and HYPO conditions. 3) The 
amylin-induced phosphorylation of ERK in the AP is not affected by 
hypoglycemia. 
4.1. Hypoglycemia attenuates acute amylin-induced inhibition of food 
intake 
To test our hypothesis that hypoglycemia may influence the effec-
tiveness of amylin to reduce eating, we set out to develop a new glycemic 
clamp paradigm which allowed freely-moving rats to eat while also 
maintaining a constant glycemic level via hyperinsulinemic clamp in-
fusions. Upon establishing the clamp protocol, we first determined that 
the hyperinsulinemic clamp itself does not influence amylin action by 
performing the experiment under euglycemia conditions. The eating 
inhibitory effect of amylin in rats subjected to the EU clamp was 
consistent with the well-known function of amylin to significantly 
reduce food intake [14,15]. These results therefore confirmed that 
neither the clamp nor the hyperinsulinemic state had an effect on 
amylin’s action. 
When we performed a hyperinsulinemic HYPO clamp, we observed 
that the acute amylin-induced reduction in food intake was attenuated. 
While food intake following amylin was similarly reduced during the 
first 30 min in both glycemic states, the potency of amylin to reduce 
eating was lessened at the 60 min timepoint during hypoglycemia. We 
did not, however, observe a complete blockade of amylin’s inhibitory 
effect on eating, which had been previously shown for amylin’s effect on 
gastric emptying under hypoglycemic conditions [3-5]. As discussed 
below, this disparity likely reflects the different levels of hypoglycemia 
achieved in these studies. 
4.2. Amylin treatment results in higher GIR in both EU and HYPO clamps 
Our study clearly demonstrates that when amylin is administered 
immediately prior to a meal, the appearance of prandial blood glucose is 
dramatically reduced, as is evidenced by the increased GIR necessary to 
keep amylin-treated rats at the same target glycemic level as vehicle- 
treated rats. The impact of amylin on glucose was observed within mi-
nutes after amylin injection, and it is therefore unlikely to be a direct 
consequence of the reduction in food intake measured at 30 and 60 min. 
While it was not systematically quantified, we observed no differences in 
the short latency to begin eating when food was made available between 
saline- and amylin-treated rats, which had been fasted for 18 h. Over the 
course of our pilot and primary experiments, we observed that in order 
to tightly maintain the clamped concentration in freely-feeding rats, GIR 
must be lowered already prior to the first blood sample after meal onset 
in the vehicle-treated groups. This was not the case in rats treated with 





































Fig. 4. Amylin treatment leads to the phosphorylation 
of ERK in the area postrema under euglycemic and 
hypoglycemic conditions. Mean ± SD number of pERK- 
positive cells per section of AP quantified is shown (A) 
for rats maintained at a euglycemic (EU) level and 
treated with saline (white bar, n = 4) or amylin (black 
bar, n = 5), or maintained at a hypoglycemic (HYPO) 
level and treated with saline (white bar, n = 5) or 
amylin (black bar, n = 5). Representative photomicro-
graphs are shown from the hypoglycemic/saline group 
(B) and the hypoglycemic/amylin (C) group. Data are 
expressed as mean ± SD; symbols denote significant 
differences between saline- and amylin-treated groups; 
*p<0.05, **p<0.01.   
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actually necessary to increase GIR above the level before the rats started 
to eat. This is consistent with delayed glucose excursions observed in 
volunteers that were either healthy or suffering from Type 1 diabetes 
after treatment with the amylin analogue pramlintide [16, 17]. One 
caveat of these studies was that 50% less insulin was administered on the 
test days when pramlintide was given (per standard FDA recommen-
dations to prevent hypoglycemia [18]), raising the question if lower 
insulin levels contributed to the reduced glucose excursions [16]. In the 
present study, however, insulin infusions were steady across all clamps, 
and insulin measured in the blood was not different in any condition, 
thus demonstrating that the effect of amylin to delay glucose appearance 
occurs even when insulin levels are matched. 
Because amylin both increased GIR and reduced eating in rats 
maintained in either a HYPO or EU state, we can conclude that this level 
of hypoglycemia (between 55 and 60 mg/dL) does not completely block 
the ability of amylin to limit blood glucose appearance or reduce food 
intake. Amylin was less effective at reducing food intake in the HYPO 
rats, but there still was an observable and significant effect on eating. 
The idea of a hypoglycemic brake on amylin function was based on data 
showing that amylin failed to reduce gastric emptying or suppress 
glucagon release under hypoglycemic conditions [3, 19, 20]. A key 
factor mediating this effect, however, was the induction of extreme 
hypoglycemic states; at 2.5 mmol/l (45 mg/dL), approximately 95% of 
amylin action on gastric emptying was suppressed. At a glycemic level 
more comparable to that used in the present study (55 mg/dL), 
extrapolation from the dose-response curve indicated that the reduction 
in the suppression of gastric emptying was ~50%, which is similar to the 
observed reduction in amylin’s eating-inhibitory effect [3]. Based on our 
pilot studies, in which we observed that rats clamped lower than 55 
mg/dL would begin showing fine motor deficits that could influence 
their ability to eat, we opted to target a glucose level above this 
threshold. Collectively, these data refine the idea of a hypoglycemic 
brake on amylin action, demonstrating that, while attenuated, amylin 
retains some capacity to reduce eating and limit the appearance of 
glucose in the blood under the hypoglycemic conditions tested. 
4.3. Amylin-induced phosphorylation of ERK in the AP is not affected by 
hypoglycemia 
The AP is not only an important brain area in amylin sensing, but can 
also sense changes in blood glucose levels [21]. This co-sensitivity has 
been hypothesized to play an important functional role during hypo-
glycemia [9]. AP neurons that are excited by amylin show reduced 
spontaneous in vitro activity at hypoglycemic levels; the lower the 
glucose, the lower neuronal activity [9]. In the present study, we showed 
that low glucose levels attenuate amylin’s effect on food intake, sug-
gesting that a normal or elevated plasma glucose level is a necessary 
precondition for the full satiating effect of amylin to occur. As the 
mechanisms influencing this difference are still unclear, we tested the 
hypothesis that euglycemic levels are permissive of amylin-induced 
phosphorylation of ERK in the AP. We previously showed that periph-
eral amylin treatment induces pERK in the AP, with peak expression of 
pERK detected at 15 min after treatment [6]. We also found that pERK 
was functionally relevant for amylin action, as blockade of ERK phos-
phorylation with the MEK inhibitor U0126 in the fourth ventricle 
blunted the food intake-reducing effect of peripheral amylin under 
certain conditions [6]. We anticipated that the attenuation of amylin’s 
eating inhibitory effect under hypoglycemic conditions would correlate 
with a decreased number of pERK-positive neurons after amylin treat-
ment in the HYPO rats compared to EU. We observed, however, that the 
number of pERK-positive cells per AP section was similar in the two 
glycemic states; this was true for saline as well as for amylin-injected 
rats. Consistent with our previous findings [6], amylin significantly 
increased pERK levels compared to saline after 15 min, and this was true 
in both EU and HYPO states. 
Hence, we have seen an attenuated food intake-reducing response of 
amylin during hypoglycemia, but no change in the pERK formation in 
the AP. As we showed previously that ERK phosphorylation plays a role 
in amylin action [6], it seems that the effect of hypoglycemia on amy-
lin’s satiating response is located downstream or is independent of the 
ERK phosphorylation. We have observed a similar dichotomy in rats 
lacking function leptin receptors—the satiating effect of amylin was 
reduced in the absence of the leptin receptor, but neurons in the AP still 
mounted a normal Fos response following amylin treatment [10]. In 
both cases, it seems that amylin is still capable of activating AP neurons, 
but the ability of hypoglycemia (present study) or loss of leptin signaling 
[10] to limit amylin-induced reduction of food intake is located down-
stream of the activation of either pERK or Fos, respectively, in the AP. 
The lateral parabrachial nucleus, for example, is a brain nucleus that is 
both targeted by amylin-activated AP neurons [22, 23], and sensitive to 
changes to glucose levels [24], therefore representing a potential sec-
ondary site of convergence for amylin and glucose signaling. It is also 
possible that the mere presence of pERK in the AP tells us little about 
how it is altering cell function. Interestingly, a recent study delineated a 
link between neuronal activity pattern and subsequent changes in gene 
expression profile, which is mediated by MAPK/ERK signaling pathways 
[25], such that brief or sustained neuronal activity led to different pat-
terns of gene expression, though both were dependent on MAPK/ERK 
signaling. Based on data showing that glucose levels can alter firing rates 
of amylin-sensitive neurons [9], it is possible that low glucose levels can 
modulate the activity pattern of amylin-activated cells, which has the 
potential to alter the downstream consequences of phosphorylated ERK 
without altering the presence of amylin-induced pERK. 
4.4. Future directions and conclusion 
Perhaps the most striking finding from this study was the dramatic 
increase in GIR necessary to offset amylin’s stark reduction of the 
appearance of prandial blood glucose, and the fact that this was 
observed in both euglycemic and hypoglycemic conditions. One plau-
sible explanation for these findings is that amylin’s suppression of meal- 
stimulated glucagon secretion contributes greatly to this outcome. 
Glucagon helps to maintain glycemia at a healthy level by promoting 
glycogenolysis [26] and gluconeogenesis [27], and its release is stimu-
lated by both hypoglycemia and in response to nutrients [20]. Thus, due 
to the suppression of nutrient-stimulated glucagon secretion by amylin 
treatment, more exogenous glucose was required to maintain the tar-
geted level of glycemia. What remains to be understood, is why the 
difference in GIR between saline- and amylin-treated rats was even 
greater during the HYPO clamp than during the EU (a difference of 
approximately 40 mg/kg/min glucose during HYPO versus 20 
mg/kg/min during EU). Based on the evidence that hypoglycemia limits 
amylin’s ability to suppress glucagon [5], we would have hypothesized a 
smaller difference in GIR during the HYPO clamp; due to the hypogly-
cemic brake on amylin action, glucagon’s counterregulation of the hy-
poglycemia should still be intact. There is evidence that 
counterregulatory hormones, such as norepinephrine, epinephrine and 
glucagon, were similar in humans receiving pramlintide or placebo 
during hypoglycemia [28]. However, future studies are needed to 
compare levels of glucagon to confirm the role of glucagon in the 
observed GIR effect, and whether this role varies under HYPO and EU 
conditions. Additionally, use of isotopic glucose tracer would be a 
valuable way to determine how quickly glucose is absorbed from the 
carbohydrates in the food, to determine the precise contribution of 
endogenous and exogenous glucose to the blood glucose levels measured 
during the clamps, and to understand how amylin and glycemic state 
influence these processes. 
In conclusion, the data presented here add several insights into the 
posited brake that hypoglycemia places on amylin action. For more than 
two decades, it has been known that under hypoglycemic conditions 
amylin’s ability to suppress glucagon release and slow gastric emptying 
are reduced. Here we demonstrate using a novel glycemic clamp 
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paradigm that hypoglycemia also attenuates the food intake-reducing 
effect of amylin in rats. We also showed that amylin quickly limits 
prandial blood glucose appearance, as evidenced by the pre-emptive and 
sustained increases in GIRs required to clamp blood glucose at either a 
hypoglycemic or euglycemic state following amylin treatment at meal 
onset. Finally, we showed hypoglycemia does not influence amylin’s 
ability to activate the ERK signaling pathway in AP neurons. 
Declaration of Competing Interest 
Authors declare the following potential conflict of interest. TAL has 
received research support from Novo Nordisk and Boehringer Ingel-
heim; the supported projects are unrelated to the research shown here. 
The remaining authors have no potential conflicts of interest. 
Acknowledgment(s) 
This work was supported by the Swiss National Science Foundation 
(to T. A. Lutz). 
References 
[1] A. Young, Amylin and the integrated control of nutrient influx. Advances in 
Pharmacology, Academic Press, 2005, pp. 67–77. 
[2] D.L. Hay, S. Chen, T.A. Lutz, D.G. Parkes, J.D. Roth, Amylin: pharmacology, 
physiology, and clinical potential, Pharmacol Rev 67 (3) (2015) 564–600. 
[3] B.R. Gedulin, A.A. Young, Hypoglycemia overrides amylin-mediated regulation of 
gastric emptying in rats, Diabetes 47 (1) (1998) 93–97. 
[4] B.R. Gedulin, C.M. Jodka, K. Herrmann, A.A. Young, Role of endogenous amylin in 
glucagon secretion and gastric emptying in rats demonstrated with the selective 
antagonist, AC187, Regul. Pept. 137 (3) (2006) 121–127. 
[5] B.R. Gedulin, T.J. Rink, A.A. Young, Dose-response for glucagonostatic effect of 
amylin in rats, Metabolism 46 (1) (1997) 67–70. 
[6] C.S. Potes, C.N. Boyle, P.J. Wookey, T. Riediger, T.A. Lutz, Involvement of the 
extracellular signal-regulated kinase 1/2 signaling pathway in amylin’s eating 
inhibitory effect, Am J Physiol Regul Integr Comp Physiol 302 (3) (2012) 
R340–R351. 
[7] F.E. Braegger, L. Asarian, K. Dahl, T.A. Lutz, C.N. Boyle, The role of the area 
postrema in the anorectic effects of amylin and salmon calcitonin: behavioral and 
neuronal phenotyping, Eur J Neurosci 40 (7) (2014) 3055–3066. 
[8] G.L. Edwards, B.R. Gedulin, J. C., R.P. Dilts, M. C.C., A. Young, Area postrem (AP)- 
lesions block the regulation of gastric emptying by amylin, Neurogastroenterol 
Motil 10 (1998) 26. 
[9] T. Riediger, H.A. Schmid, T.A. Lutz, E. Simon, Amylin and glucose co-activate area 
postrema neurons of the rat, Neurosci Lett 328 (2) (2002) 121–124. 
[10] S. Duffy, T.A. Lutz, C.N. Boyle, Rodent models of leptin receptor deficiency are less 
sensitive to amylin, Am J Physiol Regul Integr Comp Physiol 315 (4) (2018) 
R856–R865. 
[11] M. Bohland, A.V. Matveyenko, M. Saberi, A.M. Khan, A.G. Watts, C.M. Donovan, 
Activation of hindbrain neurons is mediated by portal-mesenteric vein 
glucosensors during slow-onset hypoglycemia, Diabetes 63 (8) (2014) 2866–2875. 
[12] D.G. Maggs, M. Fineman, J. Kornstein, T. Burrell, S. Schwartz, Y. Wang, J. 
A. Ruggles, O.G. Kolterman, C. Weyer, Pramlintide reduces postprandial glucose 
excursions when added to insulin lispro in subjects with type 2 diabetes: a dose- 
timing study, Diabetes Metab Res Rev 20 (1) (2004) 55–60. 
[13] C. Weyer, D.G. Maggs, A.A. Young, O.G. Kolterman, Amylin replacement with 
pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: 
a physiological approach toward improved metabolic control, Curr Pharm Des 7 
(14) (2001) 1353–1373. 
[14] T.A. Lutz, N. Geary, M.M. Szabady, E. Del Prete, E. Scharrer, Amylin decreases 
meal size in rats, Physiol Behav 58 (6) (1995) 1197–1202. 
[15] U. Arnelo, J. Permert, T.E. Adrian, J. Larsson, P. Westermark, R.D. Reidelberger, 
Chronic infusion of islet amyloid polypeptide causes anorexia in rats, Am J Physiol 
271 (6 Pt 2) (1996) R1654–R1659. 
[16] L. Hinshaw, M. Schiavon, A. Mallad, C.D. Man, R. Basu, A.E. Bharucha, C. Cobelli, 
R.E. Carter, A. Basu, Y.C. Kudva, Effects of delayed gastric emptying on 
postprandial glucose kinetics, insulin sensitivity, and beta-cell function, Am J 
Physiol Endocrinol Metab 307 (6) (2014) E494–E502. 
[17] L. Hinshaw, M. Schiavon, V. Dadlani, A. Mallad, C. Dalla Man, A. Bharucha, 
R. Basu, J.R. Geske, R.E. Carter, C. Cobelli, A. Basu, Y.C. Kudva, Effect of 
pramlintide on postprandial glucose fluxes in type 1 diabetes, J Clin Endocrinol 
Metab 101 (5) (2016) 1954–1962. 
[18] G.J. Ryan, L.J. Jobe, R. Martin, Pramlintide in the treatment of type 1 and type 2 
diabetes mellitus, Clin Ther 27 (10) (2005) 1500–1512. 
[19] A. Young, Role of amylin in nutrient intake - animal studies, Diabet Med 14 (Suppl 
2) (1997) S14–S18. 
[20] A. Young, Inhibition of glucagon secretion, Adv Pharmacol 52 (2005) 151–171. 
[21] A. Adachi, M. Kobashi, M. Funahashi, Glucose-responsive neurons in the 
brainstem, Obes Res 3 (5) (1995) 735S–740S. Suppl. 
[22] C.S. Potes, T.A. Lutz, T. Riediger, Identification of central projections from amylin- 
activated neurons to the lateral hypothalamus, Brain Res 1334 (2010) 31–44. 
[23] L. Boccia, C.Le Foll, T.A. Lutz, Noradrenaline signaling in the LPBN mediates 
amylin’s and salmon calcitonin’s hypophagic effect in male rats, FASEB J 34 (11) 
(2020) 15448–15461. 
[24] A.S. Garfield, B.P. Shah, J.C. Madara, L.K. Burke, C.M. Patterson, J. Flak, R.L. Neve, 
M.L. Evans, B.B. Lowell, M.G. Myers,  Jr., L.K. Heisler, A parabrachial- 
hypothalamic cholecystokinin neurocircuit controls counterregulatory responses to 
hypoglycemia, Cell Metab 20 (6) (2014) 1030–1037. 
[25] K.M. Tyssowski, N.R. DeStefino, J.H. Cho, C.J. Dunn, R.G. Poston, C.E. Carty, R. 
D. Jones, S.M. Chang, P. Romeo, M.K. Wurzelmann, J.M. Ward, M.L. Andermann, 
R.N. Saha, S.M. Dudek, J.M. Gray, Different Neuronal Activity Patterns Induce 
Different Gene Expression Programs, Neuron, 98 (3) (2018) 530–546, e11. 
[26] C.J. Ramnanan, D.S. Edgerton, G. Kraft, A.D. Cherrington, Physiologic action of 
glucagon on liver glucose metabolism, Diabetes Obes Metab 13 (1) (2011) 
118–125. Suppl. 
[27] A. Gastaldelli, E. Toschi, M. Pettiti, S. Frascerra, A. Quinones-Galvan, A.M. Sironi, 
A. Natali, E. Ferrannini, Effect of physiological hyperinsulinemia on 
gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients, Diabetes 
50 (8) (2001) 1807–1812. 
[28] T. Heise, L. Heinemann, S. Heller, C. Weyer, Y. Wang, S. Strobel, O. Kolterman, 
D. Maggs, Effect of pramlintide on symptom, catecholamine, and glucagon 
responses to hypoglycemia in healthy subjects, Metabolism 53 (9) (2004) 
1227–1232. 
M. Honegger et al.                                                                                                                                                                                                                              
